Strategic Acquisition of SiVantage
The acquisition of SiVantage was a significant focus of Q2, expected to enhance commercial organization, unlock new pathways, and drive sustainable top line growth.
Advancement of Catamaran Platform
Successful integration of Catamaran into lumbar fusion constructs, supported by FDA clearance, opens new market opportunities and expands footprint in the sacropelvic fixation space.
Financial Discipline
Operating expenses reduced by 29% year-over-year, demonstrating tighter discipline while preserving investments in growth strategy.
Cash Position and No Debt
Ended the quarter with $7.8 million in cash and no debt, providing flexibility to continue executing strategic roadmap.
Upcoming Product Launches
Full commercial launch of Catamaran SE platform and initial alpha surgeries for Symmetry Plus system expected to begin in Q4.